• Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Has MELD-Na Improved Outcomes of Patients on the Liver Transplant Waitlist?

Liver allocation based on model for end-stage liver disease-sodium (MELD-Na) score improved waitlist outcomes and provided significant benefit to patients with hyponatremia, researchers report in the November issue of Gastroenterology. However, there are discrepancies in transplantation survival benefit, so current rules for liver allocation might require revision, the authors state. The

Read more
  • Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

In a pilot study from the October issue of Clinical Gastroenterology and Hepatology, colony stimulating factor 3 (CSF3, also called GCSF) improved liver function and increased survival times in patients with severe alcohol-associated hepatitis (AH), compared with standard therapy. Addition of N-acetyl cysteine (NAC) to GCSF did not improve patient outcomes. Patients

Read more
  • What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

What are the Effects of Prednisolone in Patients With Severe Alcoholic Liver Disease?

Infections are frequent in patients with severe alcoholic liver disease, but are only independently associated with mortality when patients receive prednisolone, researchers report in the April issue of Gastroenterology. This could offset prednisolone’s therapeutic benefit. This study’s senior author, Mark Thursz, discusses the findings in a video abstract. As with

Read more
  • Probiotics for Cirrhosis?

Probiotics for Cirrhosis?

A probiotic solution significantly reduced the risk of hospitalization for hepatic encephalopathy and markers of liver disease severity in patients with cirrhosis, researchers report in the December issue of Gastroenterology. Hepatic encephalopathy develops in 50%–70% of patients with cirrhosis; fewer than 50% of these patients survive for 1 year. Rifaximin and

Read more